足弓与血管体分类联合WIfI分期预测CLTI截肢与创面愈合
高WIfI风险联合足弓B或C组的串联组合总体准确率最高(0.781),且高WIfI风险与高足弓风险均独立预测创面愈合时间延长。
要点
- 高WIfI风险联合足弓B或C组的串联组合预测截肢总体准确率达0.781。
- 高WIfI风险与高足弓风险均独立预测创面愈合时间延长。
- 吸烟是唯一与截肢相关的基线特征(75.0% vs 42.0%,P=0.009)。
核心结论
- 足弓与血管体评估在WIfI分期之外提供额外预后信息,联合可改善截肢与创面愈合预测。
- 高WIfI风险且足弓状态受损者不良结局风险最高,或可从强化创面护理与密切监测中获益。
研究设计与样本
- 每例患者接受WIfI分期(低或高风险)并归入3个足弓组之一:A组(足弓完整或足弓不完整但血管体直接供血至创面)、B组(足弓不完整且血管体间接供血,或足弓缺如但血流来自与创面相同血管体区域)、C组(足弓缺如且无直接血管体供血)。
- 足弓分类基于血运重建后完成DSA进行,评估7个预设二元预测模型。
- 采用多变量逻辑回归和线性回归,调整年龄、性别、吸烟状态、糖尿病、高血压、缺血性心脏病和肾功能不全。
主要发现
- 平均年龄61±9岁,男性占76.4%。
- 69例(77.5%)实现保肢,20例(22.5%)截肢。
- 高WIfI风险联合足弓B或C组的串联组合总体准确率最高(0.781;95%CI 0.681-0.862),敏感度75.0%、特异度81.2%、阳性预测值53.6%、阴性预测值91.8%;调整OR 15.951(95%CI 3.952-64.372;P<0.001)。
- WIfI单独调整OR 27.968(95%CI 3.381-231.35;P=0.002);足弓C组单独调整OR 5.969(95%CI 1.719-20.727;P=0.005)。
- 高WIfI风险(B=1.334;P<0.001)和高足弓风险(B=1.037;P=0.001)均独立预测创面愈合时间延长;吸烟是唯一与截肢相关的基线特征(75.0% vs 42.0%;P=0.009)。
临床怎么用
- 对CLTI患者血运重建后行足弓与血管体评估,联合WIfI分期识别高风险患者。
- 高WIfI风险且足弓状态受损者应考虑强化创面护理、密切监测及再次干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate whether a three-group foot arch and angiosome classification adds independent predictive value for limb amputation and wound healing duration when combined with the Wound, Ischemia, and foot Infection (WIfI) staging system in patients with chronic limb-threatening ischemia (CLTI) using 7 prespecified predictive models. DESIGN: Prospective observational cohort study. METHODS: Eighty-nine consecutive CLTI patients were enrolled from a tertiary vascular center over 12 months. Each patient underwent WIfI staging (low or high risk) and was assigned to one of 3 foot arch groups: Group A (complete pedal arch or incomplete arch with direct angiosome supply to the wound), Group B (incomplete arch with indirect angiosome supply or absent arch with inflow from the same angiosome territory as the wound), or Group C (absent arch with no direct angiosome supply). Foot arch classification was performed on completion DSA following revascularization. Seven prespecified binary predictive models were evaluated, including WIfI alone, 2 foot-arch only models, and 4 serial or parallel combinations. Diagnostic indices including overall accuracy were computed, and multivariable logistic and linear regression were performed with adjustment for age, sex, smoking status, diabetes mellitus, hypertension, ischemic heart disease, and renal insufficiency. RESULTS: Mean age was 61 ± 9 years; 76.4% were male. Limb salvage was achieved in 69 patients (77.5%); 20 underwent amputation (22.5%). The serial combination of high WIfI risk and foot arch Groups B or C achieved the highest overall accuracy (0.781; 95% confidence interval [CI], 0.681-0.862), with sensitivity 75.0%, specificity 81.2%, positive predictive value 53.6%, and negative predictive value 91.8%; adjusted odds ratio (OR), 15.951 (95% CI, 3.952-64.372; P < 0.001). WIfI alone yielded adjusted OR, 27.968 (95% CI, 3.381-231.35; P = 0.002). Foot arch Group C alone yielded adjusted OR, 5.969 (95% CI, 1.719-20.727; P = 0.005). Both high WIfI risk (B = 1.334; P < 0.001) and high foot arch risk (B = 1.037; P = 0.001) independently predicted prolonged wound healing duration. Smoking was the only baseline characteristic associated with amputation (75.0% vs. 42.0%; P = 0.009). CONCLUSION: Pedal arch and angiosome assessment provide additional prognostic information beyond WIfI staging alone in patients with CLTI. Incorporating these parameters into risk assessment may improve prediction of both limb loss and wound healing outcomes. Patients with concurrent high WIfI risk and compromised pedal arch status demonstrated the greatest risk of adverse outcomes and may benefit from escalated wound care, closer surveillance and consideration of repeat intervention following revascularization.
引用
- Hanna ASH, Mohamed AA, Hameed Desouki AA, et al. Pedal Arch and Angiosome Classification Combined with the Wound, Ischemia, and Foot Infection Staging System for Prediction of Limb Amputation and Wound Healing in Chronic Limb-Threatening Ischemia: A Prospective Cohort Study. Ann Vasc Surg. 2026. PMID: 42575265. doi:10.1016/j.avsg.2026.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。